{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T02:05:37Z","timestamp":1771553137766,"version":"3.50.1"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This retrospective, observational study examined the safety and efficacy of the Janus kinase inhibitor peficitinib in Japanese patients with rheumatoid arthritis who switched to peficitinib due to inadequate response to biologic disease-modifying antirheumatic drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included patients aged\u2009\u2265\u200920\u00a0years with rheumatoid arthritis who switched to peficitinib between 10 July 2019 and 31 March 2022 and were enrolled in peficitinib post-marketing surveillance. The primary endpoint was change in disease activity score in 28 joints with erythrocyte sedimentation rate (DAS28-ESR) from index date to 24\u00a0weeks. Secondary endpoints included change in Clinical Disease Activity Index and adverse event incidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 76 enrolled patients, efficacy data were available for 67; 56 completed 24\u00a0weeks of treatment. One-quarter (19\/76) of patients reported adverse events; 16 (21.1%) had drug-related adverse events with one (streptococcal infection) considered serious. From index date to 24\u00a0weeks, mean (standard deviation) change in DAS28-ESR was \u22120.95 (1.24) (95% confidence interval [CI]: \u22121.26, \u22120.65; P\u00a0&amp;lt;\u2009.0001) and in Clinical Disease Activity Index was \u22127.82 (8.52) (95% CI: \u22129.90, \u22125.74; P\u00a0&amp;lt;\u2009.0001). Improvements in DAS28-ESR and Clinical Disease Activity Index by 12 and 24\u00a0weeks were statistically significant regardless of prior number of biologic disease-modifying antirheumatic drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Peficitinib could be an effective treatment option for patients with rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roaf043","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T07:32:13Z","timestamp":1748935933000},"page":"808-819","source":"Crossref","is-referenced-by-count":1,"title":["A retrospective chart review to explore the efficacy and safety of switching to peficitinib in Japanese patients with rheumatoid arthritis and inadequate response to biologic disease-modifying antirheumatic drugs"],"prefix":"10.1093","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8858-9435","authenticated-orcid":false,"given":"Kunihiro","family":"Yamaoka","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Kitasato University School of Medicine , Sagamihara-shi, Kanagawa ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Kondo","sequence":"additional","affiliation":[{"name":"Kitasato University Medical Center , Saitama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshinori","family":"Furuya","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc. , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc. , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadatsura","family":"Koshika","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc. , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Morita","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc. , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Oku","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kitasato University School of Medicine , Sagamihara-shi, Kanagawa ,","place":["Japan"]},{"name":"Department of Rheumatology, Tokai University School of Medicine , Isehara, Kanagawa ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"2026021908163833200_ref1","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026021908163833200_ref2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/mr\/roac017","article-title":"Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication","volume":"33","author":"Kawahito","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2026021908163833200_ref3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026021908163833200_ref4","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet."},{"key":"2026021908163833200_ref5","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"2026021908163833200_ref6","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1093\/rheumatology\/key280","article-title":"The JAK inhibitors: do they bring a paradigm shift for the management of rheumatic diseases?","volume":"58","author":"Tanaka","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2026021908163833200_ref7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3904\/kjim.2015.137","article-title":"Current concepts in the management of rheumatoid arthritis","volume":"31","author":"Tanaka","year":"2016","journal-title":"Korean J Intern Med"},{"key":"2026021908163833200_ref8","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1080\/14656566.2023.2247325","article-title":"Making a prescribing choice for rheumatoid arthritis: a focus on small molecule drugs vs. biologics for the most favourable patient outcome","volume":"24","author":"Tanaka","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"2026021908163833200_ref9","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/rheumatology\/kex489","article-title":"Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis","volume":"57","author":"Genovese","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2026021908163833200_ref10","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","article-title":"Trial of upadacitinib or abatacept in rheumatoid arthritis","volume":"383","author":"Rubbert-Roth","year":"2020","journal-title":"N Engl J Med"},{"key":"2026021908163833200_ref11","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1111\/1756-185X.13731","article-title":"Clinical effectiveness and safety of additional administration of tacrolimus in rheumatoid arthritis patients with an inadequate response to abatacept: a retrospective cohort study","volume":"22","author":"Suzuki","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"2026021908163833200_ref12","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet."},{"key":"2026021908163833200_ref13","volume-title":"Study of CP-690,550 Versus Placebo in Rheumatoid Arthritis Patients on Background Methotrexate with Inadequate Response to Tumor Necrosis Factor (TNF) Inhibitors","author":"Pfizer","year":"2018"},{"key":"2026021908163833200_ref14","volume-title":"A Study to Evaluate Safety and Efficacy of ASP015K in Patients with Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs","author":"Astellas Pharma Inc","year":"2020"},{"key":"2026021908163833200_ref15","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet."},{"key":"2026021908163833200_ref16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA."},{"key":"2026021908163833200_ref17","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med"},{"key":"2026021908163833200_ref18","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1093\/rheumatology\/keaa858","article-title":"Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway","volume":"60","author":"Fitton","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2026021908163833200_ref19","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/14397595.2020.1836789","article-title":"A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years","volume":"31","author":"Takeuchi","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2026021908163833200_ref20","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/14397595.2020.1794103","article-title":"Efficacy and safety of peficitinib in rheumatoid arthritis","volume":"30","author":"Kaneko","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2026021908163833200_ref21","article-title":"Safety and efficacy of peficitinib in Asian patients with rheumatoid arthritis who had an inadequate response or intolerance to methotrexate: results of a multicenter, randomized, double-blind, placebo-controlled phase 3 study","volume":"42","author":"Yang","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"key":"2026021908163833200_ref22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR definition of difficult-to-treat rheumatoid arthritis","volume":"80","author":"Nagy","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026021908163833200_ref23","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/art.1780350502","article-title":"The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis","volume":"35","author":"Hochberg","year":"1992","journal-title":"Arthritis Rheum"},{"key":"2026021908163833200_ref24","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/jama.1949.02900430001001","article-title":"Therapeutic criteria in rheumatoid arthritis","volume":"140","author":"Steinbrocker","year":"1949","journal-title":"J Am Med Assoc"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roaf043\/63440010\/roaf043.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/35\/5\/808\/63440010\/roaf043.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/35\/5\/808\/63440010\/roaf043.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:16:48Z","timestamp":1771507008000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/35\/5\/808\/8157182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,6,5]]},"published-print":{"date-parts":[[2025,9,2]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roaf043","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,6,5]]}}}